Fajardo-Ramírez ÓR, Salas-Alanis JC, Guzmán-Huerta E, Martínez U, Barbosa Á, Sean-Patrick Scott, Hernández-Hernández JA, Villela LM

Language: English
References: 5
Page: 288-290
PDF size: 96.05 Kb.

Text Extraction

According to the American Cancer Society, metastatic melanoma represents only 5% of all dermatology malignancies in the skin, but it is responsible for 80% of all deaths. Due to a delay in diagnosis, it is estimated that only 14% of patients survive 5 years after diagnosis.

REFERENCES

1. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006; 355: 51-65.

2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011; 30; 364(26): 2507-16.

3. Flaherty KT, McArthur G. BRAF, a Target in Melanoma. Cancer 2012; 116: 4902-13.

4. Si L, Kong Y, Xu X, Flaherty KT, Sheng X, Cui C, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 2012; 48(1): 94-100.

5. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigomaligna subtypes. J Invest Dermatol 2005; 125(3): 575-9.